Vedolizumab, A New Treatment for Ulcerative Colitis & Crohn's Disease Looks Promising - Info & Clinical Trial Included

Vedolizumab, a potentially new treatment for UC and Crohn's disease is being fast tracked for review by the FDA.  The BLA (biologics license application) will give priority review to the ulcerative colitis application and standard review to the Crohn's disease application.
The part of the clinical trial that is most important to me is the said adverse effects that were found in the patients who participated in the study.  Based on the concluding trial results, the adverse effects of the drug is said to be the same as the placebo.  That's great news.  I'm going to continue to watch this drug for new updates and news pertaining to safety. So far, this new treatment by Takeda Pharmaceuticals looks promising.
I have also included the clinical trial abstract below.  

Gastroenterology & Endoscopy News - New IBD Drug, Vedolizumab, Receives Priority Review Status for Ulcerative Colitis: 

On Sept. 4, Takeda Pharmaceutical Company Ltd., announced that it received priority review status from the FDA for its drug vedolizumab, an investigational antibody for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). Takeda submitted a biologics license application (BLA) to the FDA in June for the treatment of CD and UC; the UC application will receive priority review, and the application for CD will be reviewed under the standard timeline.

Pfizer’s Experimental Drug Works for Severe Ulcerative Colitis

Depending on the severity of the disease, I would understand trying this new drug. It should be noted and expressed clearly the severe side-effects that are possible with this drug.  Not just dry mouth and headache.  I guess you would have to weigh the positives and negatives of this proposed treatment.  Do your research before you make a decision on any medication.

 HIGHLIGHTS

In the study, 78 percent of 49 patients given a 15 milligram dose experienced a reduction in symptoms; 61 percent of 33 patients given a 10 milligram dose improved.

Eight-Week Trial

Patients in the trial got Pfizer’s pill for eight weeks, though likely would take it for longer because ulcerative colitis is a chronic disease, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, who led the research

Pfizer’s Experimental Drug Works in Ulcerative Colitis - Businessweek:

'via Blog this'